Kidney transplantation in children

New England Journal of Medicine

Volumn 371, Issue 6, 2014, Pages 549-558

  Dharnidharka, Vikas R ^a   Fiorina, Paolo ^b,c   Harmon, William E ^b  

^a ST LOUIS CHILDREN S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BELATACEPT; CREATININE; RITUXIMAB;

BLADDER DYSFUNCTION; CHILD; CHILDHOOD MORTALITY; CLINICAL TRIAL (TOPIC); CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DONOR SELECTION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FOCAL GLOMERULOSCLEROSIS; GRAFT RECIPIENT; GRAFT SURVIVAL; GROWTH DISORDER; HUMAN; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; KIDNEY DYSPLASIA; KIDNEY FAILURE; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOPROLIFERATIVE DISEASE; MESENCHYMAL STEM CELL; NONHUMAN; OBSTRUCTIVE UROPATHY; PRIORITY JOURNAL; REFLUX NEPHROPATHY; REGULATORY T LYMPHOCYTE; REVIEW; STEM CELL TRANSPLANTATION; ADOLESCENT; ALLOGRAFT; CHRONIC KIDNEY FAILURE; HEALTH CARE ORGANIZATION; IMMUNOLOGY; KIDNEY; PATHOPHYSIOLOGY; PHYSIOLOGY; SURVIVAL; TRANSITION TO ADULT CARE;

ADOLESCENT; ALLOGRAFTS; CHILD; GRAFT SURVIVAL; GROWTH DISORDERS; HEALTH CARE RATIONING; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSION; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSITION TO ADULT CARE;

EID: 84905748618     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1314376     Document Type: Review

References (79)

1. Murray JE. The first successful organ transplants in man. J Am Coll Surg 2005;200:5-9. (Pubitemid 41583108)
2. Horslen S, Barr ML, Christensen LL, Ettenger R, Magee JC. Pediatric transplantation in the United States, 1996-2005. Am J Transplant 2007;7:1339-58. (Pubitemid 46606939)
3. Harmon WE. Pediatric kidney transplantation. In: Avner ED, Harmon WE, Niaudet P, Yoshikawa N, eds. Pediatric nephrology. 6th ed. Berlin: Springer-Verlag, 2009:1867-902.
4. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008;8:753-60. (Pubitemid 351347767)
5. Harmon WE. Pediatric renal transplantation. In: Himmelfarb J, Sayegh MH, eds. Chronic kidney disease, dialysis and transplantation. Philadelphia: Elsevier, 2010:591-608.
6. Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N Engl J Med 2010;363:1451-62.
7. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014;14:272-83.
8. Shearer WT, Rosenblatt HM, Gelman RS, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol 2003;112:973-80. (Pubitemid 37412068)
9. Härtel C, Adam N, Strunk T, Temming P, Müller-Steinhardt M, Schultz C. Cytokine responses correlate differentially with age in infancy and early childhood. Clin Exp Immunol 2005;142:446-53. (Pubitemid 41719840)
10. McFarland RD, Douek DC, Koup RA, Picker LJ. Identification of a human recent thymic emigrant phenotype. Proc Natl Acad Sci U S A 2000;97:4215-20. (Pubitemid 30226113)
11. Brugnoni D, Airò P, Graf D, et al. Ontogeny of CD40L [corrected] expression by activated peripheral blood lymphocytes in humans. Immunol Lett 1996;49:27-30. [Erratum, Immunol Lett 1996;52:61.] (Pubitemid 26100166)
12. Hassan J, Reen DJ. Reduced primary antigen-specific T-cell precursor frequencies in neonates is associated with deficient interleukin-2 production. Immunology 1996;87:604-8. (Pubitemid 26116470)
13. Hanna-Wakim R, Yasukawa LL, Sung P, et al. Age-related increase in the frequency of CD4(+) T cells that produce interferongamma in response to staphylococcal enterotoxin B during childhood. J Infect Dis 2009;200:1921-7.
14. Chiba Y, Higashidate Y, Suga K, Honjo K, Tsutsumi H, Ogra PL. Development of cell-mediated cytotoxic immunity to respiratory syncytial virus in human infants following naturally acquired infection. J Med Virol 1989;28:133-9. (Pubitemid 19183965)
15. Jyonouchi H, Cui C, Geng L, Yin Z, Fitzgerald-Bocarsly P. Age-dependent changes in peripheral blood dendritic cell subsets in normal children and children with specific polysaccharide antibody deficiency (SPAD). Eur J Pediatr 2010;169:1233-9.
16. Gupta A, Iveson V, Varagunam M, Bodger S, Sinnott P, Thuraisingham RC. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant? Transplantation 2008;85:1200-4. (Pubitemid 351590199)
17. Scientific Registry of Transplant Recipients. 2012 Annual data report (http://srtr.transplant.hrsa.gov/annual-reports/2012/Default.aspx).
18. North American Pediatric Renal Trials and Collaborative Studies. 2010 Annual transplant report (https://web.emmes.com/study/ped/annlrept/2010-Report. pdf).
19. McEnery PT, Stablein DM, Arbus G, Tejani A. Renal transplantation in children - a report of the North American Pediatric Renal Transplant Cooperative Study. N Engl J Med 1992;326:1727-32.
20. Mitchell ME, Balcom AH. Bladder dysfunction in children. In: Avner ED, Harmon WE, Niaudet P, Yoshikawa N, eds. Pediatric nephrology. 6th ed. Berlin: Springer-Verlag, 2009:1379-404.
21. Dharnidharka VR, Agodoa LY, Abbott KC. Effects of urinary tract infection on outcomes after renal transplantation in children. Clin J Am Soc Nephrol 2007;2:100-6.
22. Neu AM, Fivush BA. Recommended immunization practices for pediatric renal transplant recipients. Pediatr Transplant 1998;2:263-9. (Pubitemid 128539689)
23. Organ Procurement and Transplantation Network. Allocation of deceased kidneys. Washington, DC: Department of Health and Human Services, 2010 (http://optn.transplant.hrsa.gov/PoliciesandBylaws2/policies/pdfs/policy-7.pdf).
24. Reese PP, Hwang H, Potluri V, Abt PL, Shults J, Amaral S. Geographic determinants of access to pediatric deceased donor kidney transplantation. J Am Soc Nephrol 2014;25:827-35.
25. Moudgil A, Dharnidharka VR, Lamb KE, Meier-Kriesche HU. Best allograft survival from share-35 kidney donors occurs in middle-aged adults and young children - an analysis of OPTN data. Transplantation 2013;95:319-25.
26. Harmon WE, Alexander SR, Tejani A, Stablein D. The effect of donor age on graft survival in pediatric cadaver renal transplant recipients - a report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation 1992;54:232-7.
27. Li L, Chang A, Naesens M, et al. Steroid-free immunosuppression since 1999: 129 pediatric renal transplants with sustained graft and patient benefits. Am J Transplant 2009;9:1362-72.
28. Sarwal MM, Cecka JM, Millan MT, Salvatierra O Jr. Adult-size kidneys without acute tubular necrosis provide exceedingly superior long-term graft outcomes for infants and small children: a single center and UNOS analysis. Transplantation 2000;70:1728-36. (Pubitemid 32064828)
29. Dharnidharka VR, Stevens G, Howard RJ. En-bloc kidney transplantation in the United states: an analysis of United Network of Organ Sharing (UNOS) data from 1987 to 2003. Am J Transplant 2005;5:1513-7. (Pubitemid 40839446)
30. Salvatierra O Jr, Millan M, Concepcion W. Pediatric renal transplantation with considerations for successful outcomes. Semin Pediatr Surg 2006;15:208-17. (Pubitemid 43963390)
31. Shapiro R, Sarwal MM. Pediatric kidney transplantation. Pediatr Clin North Am 2010;57:393-400.
32. Wilson CH, Bhatti AA, Rix DA, Manas DM. Routine intraoperative stenting for renal transplant recipients. Transplantation 2005;80:877-82. (Pubitemid 41552881)
33. Thomas A, Dropulic LK, Rahman MH, Geetha D. Ureteral stents: a novel risk factor for polyomavirus nephropathy. Transplantation 2007;84:433-6. (Pubitemid 47258335)
34. Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005;5:582-94. [Erratum, Am J Transplant 2005;5:839.] (Pubitemid 40313351)
35. Riley P, Marks SD, Desai DY, Mushtaq I, Koffman G, Mamode N. Challenges facing renal transplantation in pediatric patients with lower urinary tract dysfunction. Transplantation 2010;89:1299-307.
36. Rizvi SA, Sultan S, Zafar MN, et al. Pediatric kidney transplantation in the developing world: challenges and solutions. Am J Transplant 2013;13:2441-9.
37. Dobbels F, Ruppar T, De Geest S, Decorte A, Van Damme-Lombaerts R, Fine RN. Adherence to the immunosuppressive regimen in pediatric kidney transplant recipients: a systematic review. Pediatr Transplant 2010;14:603-13.
38. Hsu DT. Biological and psychological differences in the child and adolescent transplant recipient. Pediatr Transplant 2005;9:416-21. (Pubitemid 40780376)
39. Dharnidharka VR, Cherikh WS, Abbott KC. An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation 2009;87:1019-26.
40. Dharnidharka VR, Martz KL, Stablein DM, Benfield MR. Improved survival with recent post-transplant lymphoproliferative disorder (PTLD) in children with kidney transplants. Am J Transplant 2011;11:751-8.
41. Dharnidharka VR, Abdulnour HA, Araya CE. The BK virus in renal transplant recipients - review of pathogenesis, diagnosis, and treatment. Pediatr Nephrol 2011;26:1763-74.
42. Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD. Ganciclovir and acyclovir reduce the risk of posttransplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005;5:2894-900. (Pubitemid 43923949)
43. Marks WH, Ilsley JN, Dharnidharka VR. Posttransplantation lymphoproliferative disorder in kidney and heart transplant recipients receiving thymoglobulin: a systematic review. Transplant Proc 2011;43:1395-404.
44. Dharnidharka VR, Araya CE, Wadsworth CS, McKinney MC, Howard RJ. Assessing the value of ureteral stent placement in pediatric kidney transplant recipients. Transplantation 2008;85:986-91. (Pubitemid 351543162)
45. Al Khasawneh E, Araya CE, Dharnidharka VR. Missed viral surveillance testing visits associate with full blown viral diseases in children receiving kidney transplants. Pediatr Transplant 2013;17:129-32.
46. Fine RN. Etiology and treatment of growth retardation in children with chronic kidney disease and end-stage renal disease: a historical perspective. Pediatr Nephrol 2010;25:725-32.
47. Pape L, Ehrich JH, Zivicnjak M, Offner G. Growth in children after kidney transplantation with living related donor graft or cadaveric graft. Lancet 2005;366:151-3. (Pubitemid 40991216)
48. Fine RN, Stablein D, Cohen AH, Tejani A, Kohaut E. Recombinant human growth hormone post-renal transplantation in children: a randomized controlled study of the NAPRTCS. Kidney Int 2002;62:688-96. (Pubitemid 34779783)
49. Bell LE, Bartosh SM, Davis CL, et al. Adolescent transition to adult care in solid organ transplantation: a consensus conference report. Am J Transplant 2008;8:2230-42.
50. Plotnicki L, Kohl CD, Höcker B, et al. The CERTAIN Registry: a novel, Webbased registry and research platform for pediatric renal transplantation in Europe. Transplant Proc 2013;45:1414-7.
51. Sarwal MM, Ettenger RB, Dharnidharka V, et al. Complete steroid avoidance is effective and safe in children with renal transplants: a multicenter randomized trial with three-year follow-up. Am J Transplant 2012;12:2719-29.
52. Naesens M, Salvatierra O, Benfield M, et al. Subclinical inflammation and chronic renal allograft injury in a randomized trial on steroid avoidance in pediatric kidney transplantation. Am J Transplant 2012;12:2730-43.
53. Trompeter R, Filler G, Webb NJ, et al. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol 2002;17:141-9. (Pubitemid 36076024)
54. Cooney GF, Habucky K, Hoppu K. Cyclosporin pharmacokinetics in paediatric transplant recipients. Clin Pharmacokinet 1997;32:481-95. (Pubitemid 27243649)
55. Schachter AD, Benfield MR, Wyatt RJ, et al. Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy. Pediatr Transplant 2006;10:914-9. (Pubitemid 44683635)
56. Filler G, Bendrick-Peart J, Christians U. Pharmacokinetics of mycophenolate mofetil and sirolimus in children. Ther Drug Monit 2008;30:138-42. (Pubitemid 351521639)
57. Höcker B, Weber LT, Bunchman T, Rashford M, Tönshoff B. Mycophenolate mofetil suspension in pediatric renal transplantation: three-year data from the Tricontinental Trial. Pediatr Transplant 2005;9:504-11. (Pubitemid 41153272)
58. Sarwal MM, Yorgin PD, Alexander S, et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 2001;72:13-21. (Pubitemid 32652500)
59. Mackall CL, Gress RE. Thymic aging and T-cell regeneration. Immunol Rev 1997;160:91-102. (Pubitemid 28021369)
60. De Serres SA, Mfarrej BG, Magee CN, et al. Immune profile of pediatric renal transplant recipients following alemtuzumab induction. J Am Soc Nephrol 2012;23:174-82.
61. Trzonkowski P, Zilvetti M, Chapman S, et al. Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression. Am J Transplant 2008;8:338-47.
62. Knechtle SJ, Pascual J, Bloom DD, et al. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. Am J Transplant 2009;9:1087-98.
63. Knechtle SJ. Present experience with campath-1H in organ transplantation and its potential use in pediatric recipients. Pediatr Transplant 2004;8:106-12. (Pubitemid 38508420)
64. Mota C, Martins L, Costa T, et al. Nineteen years of experience utilizing anti-T-lymphocyte globulin induction in pediatric kidney transplantation. Ann Transplant 2010;15:84-91.
65. Gurkan S, Luan Y, Dhillon N, et al. Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant 2010;10:2132-41. [Erratum, Am J Transplant 2010;10:2728.]
66. Zarkhin V, Lovelace PA, Li L, Hsieh SC, Sarwal MM. Phenotypic evaluation of B-cell subsets after rituximab for treatment of acute renal allograft rejection in pediatric recipients. Transplantation 2011;91:1010-8.
67. Genberg H, Hansson A, Wernerson A, Wennberg L, Tydén G. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant 2006;6:2418-28. (Pubitemid 44359429)
68. Chaudhuri A, Ozawa M, Everly MJ, et al. The clinical impact of humoral immunity in pediatric renal transplantation. J Am Soc Nephrol 2013;24:655-64.
69. Harmon W, Guleria I, Ikle D, et al. Children develop de novo anti-HLA antibodies (Abs) following kidney transplantation at a higher incidence than adults: an analysis of the NIH CTOT/CCTPT-02 Study. Am J Transplant 2013;13:Suppl:36-7. abstract.
70. Suthanthiran M, Schwartz JE, Ding R, et al. Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med 2013;369:20-31.
71. Muthukumar T, Dadhania D, Ding R, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005;353:2342-51. (Pubitemid 41713746)
72. Li L, Khatri P, Sigdel TK, et al. A peripheral blood diagnostic test for acute rejection in renal transplantation. Am J Transplant 2012;12:2710-8.
73. Pham MX, Teuteberg JJ, Kfoury AG, et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med 2010;362:1890-900.
74. Rostaing L, Vincenti F, Grinyó J, et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant 2013;13:2875-83.
75. Yu CC, Fornoni A, Weins A, et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 2013;369:2416-23.
76. Fiorina P, Jurewicz M, Vergani A, et al. Targeting the CXCR4-CXCL12 axis mobilizes autologous hematopoietic stem cells and prolongs islet allograft survival via programmed death ligand 1. J Immunol 2011;186:121-31.
77. Fiorina P, Jurewicz M, Augello A, et al. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol 2009;183:993-1004.
78. Tan J, Wu W, Xu X, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 2012;307:1169-77.
79. Fiorina P, Voltarelli J, Zavazava N. Immunological applications of stem cells in type 1 diabetes. Endocr Rev 2011;32:725-54.